drugset / Trial / NCT03420508
Treating Patients With Melanoma and ALK Alterations With Ensartinib
Phase 2
Active not recruiting
18 enrolled
Memorial Sloan Kettering Cancer Center
Xcovery Holdings, Inc. · collab
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to test the effects of the study drug, ensartinib, on the patient and the cancer. Ensartinib is a new, investigational type of treatment for melanoma with a particular type of abnormality.
Timeline
- Start
- 2018-01-10
- Primary completion
- 2027-01
- Completion
- 2027-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Ensartinib | Small molecule | 225 mg | Oral |